These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

613 related items for PubMed ID: 30270065

  • 1. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
    Schmidt N, Dressel A, Grammer TB, Gouni-Berthold I, Julius U, Kassner U, Klose G, König C, Koenig W, Otte B, Parhofer KG, Reinhard W, Schatz U, Schunkert H, Steinhagen-Thiessen E, Vogt A, Laufs U, März W.
    Atherosclerosis; 2018 Oct; 277():314-322. PubMed ID: 30270065
    [Abstract] [Full Text] [Related]

  • 2. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Vrablik M, Raslová K, Vohnout B, Blaha V, Satny M, Kyselak O, Vaclova M, Urbanek R, Maskova J, Soska V, Freiberger T.
    Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
    [Abstract] [Full Text] [Related]

  • 3. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    van Delden XM, Huijgen R, Wolmarans KH, Brice BC, Barron JK, Blom DJ, Marais AD.
    Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
    [Abstract] [Full Text] [Related]

  • 4. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V, Katsiki N, Makrygiannis S, Mavrogieni S, Karampetsou N, Manolis A, Melidonis A, Mikhailidis DP, Kolovou GD.
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [Abstract] [Full Text] [Related]

  • 5. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S, Boccara F, Cariou B, Carrié A, Collet X, Farnier M, Ferrières J, Krempf M, Peretti N, Rabès JP, Varret M, Vimont A, Charrière S, Bruckert E, French FH Registry group.
    Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
    Zafrir B, Jubran A.
    Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
    [Abstract] [Full Text] [Related]

  • 11. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
    Davis LE, Pogge EK.
    High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
    [Abstract] [Full Text] [Related]

  • 12. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM, Ahmad ZS, O'Brien EC, Kindt I, Shrader P, Newman CB, Pokharel Y, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW.
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH, Santos RD.
    Prog Cardiovasc Dis; 2019 Jun; 62(5):414-422. PubMed ID: 31669498
    [Abstract] [Full Text] [Related]

  • 15. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ, Hovingh GK, Catapano AL.
    Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
    [Abstract] [Full Text] [Related]

  • 16. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study.
    D'Erasmo L, Commodari D, Di Costanzo A, Minicocci I, Polito L, Ceci F, Montali A, Maranghi M, Arca M.
    Nutr Metab Cardiovasc Dis; 2020 Oct 30; 30(11):2027-2035. PubMed ID: 32830020
    [Abstract] [Full Text] [Related]

  • 17. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, Fuentes F, Diaz-Diaz JL, de Andrés R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badimón L, Mata P, SAFEHEART Investigators.
    J Am Coll Cardiol; 2016 Mar 22; 67(11):1278-85. PubMed ID: 26988947
    [Abstract] [Full Text] [Related]

  • 18. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, German Society of Nephrology (DGfN) and the Foundation of German Centers of Nephrology (DN).
    Atheroscler Suppl; 2017 Nov 22; 30():44-49. PubMed ID: 29096860
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia.
    Ginsberg HN, Tuomilehto J, Hovingh GK, Cariou B, Santos RD, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ.
    Cardiovasc Drugs Ther; 2019 Feb 22; 33(1):69-76. PubMed ID: 30734207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.